Oblato Inc.

Delaware-incorporated subsidiary of Korean biotech company GtreeBNT. Acquired exclusive worldwide rights to NHPN-1010 from Auditus LLC/Otologic Pharmaceutics in February 2020 to advance it toward Phase 2, which has not yet started for lack of funding.